A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Mycophenolate Mofetil (CellCept)

Immunosuppressant class · 24 generic manufacturers · 36 ANDAs filed at FDA.

First FDA approval1995-05-03
Generic availableYes · 24 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$101.8M in CY2024 Part D spend788K claims · 217K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.140/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.140
Across all dosage forms in distribution.
Highest NADAC
$0.140
Range is tight.
Plans with PA
1092 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Mycophenolate Mofetil used for?

Mycophenolate Mofetil is a Immunosuppressant medication tracked in Medicare Part D.

Is there a generic for Mycophenolate Mofetil?

Yes. 36 ANDAs filed at FDA, 24 generic manufacturers currently shipping.

How much does my plan pay for Mycophenolate Mofetil?

Across 329 Part D plans, Mycophenolate Mofetil averages $0.140/unit (NADAC). Lowest available: $0.140/unit. Highest in distribution: $0.140/unit.

Is Mycophenolate Mofetil on the FDA shortage list?

No. Mycophenolate Mofetil is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.